The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397
when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2
portion of the study is to find out what effects, good and/or bad, these drugs have on
patients and their metastatic breast cancer.